文章：

转移定向放射治疗对延长寡进展性转移性乳腺癌患者系统治疗疗效的研究

Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer

原文发布日期：26 June 2025

DOI: 10.3390/cancers17132153

类型: Article

开放获取: 是

英文摘要：

Background: Clinical trials have shown mixed results regarding the benefit of metastasis-directed radiation therapy (MDRT) in oligoprogressive (OP) metastatic breast cancer (MBC), leading to ongoing debate about its role. This study aimed to investigate whether MDRT can prolong the duration of systemic therapy for ≥6 months in patients with OP MBC. Methods: This retrospective cohort study included patients with MBC who received MDRT for OP disease between December 2017 and March 2023. Patients who received MDRT to the brain were excluded. Medical records were reviewed through July 2024. The primary endpoint was the proportion of patients remaining on the same systemic therapy for ≥6 months post-MDRT. Results: In total, 52 patients with OP MBC treated with MDRT were included, with 36 (69%) with HR+/HER2- disease, 10 (19%) with HER2+ disease, and 6 (12%) with TNBC. Among the 47 patients with follow-up data available, 28 (60%) remained on their systemic therapy at 6 months, including 65% (22/34) of patients with HR+/HER2- disease, 56% (5/9) with HER2+ disease, and 25% (1/4) with TNBC (p= 0.30). Among the 38 patients with a follow-up time of at least 1 year post-MDRT, 47% (18/38) remained on the same systemic therapy. The median time to next systemic therapy and median PFS were 6.9 months (95% CI, 5.7–14.7) and 6.2 months (95% CI, 4.1–9.7), respectively. Conclusions: Over half of patients with OP MBC remained on the same systemic therapy for at least 6 months following MDRT, which suggests that MDRT may help prolong systemic therapy duration for select patients.

摘要翻译： 

背景：关于转移灶定向放疗（MDRT）在寡进展性（OP）转移性乳腺癌（MBC）中的获益，临床试验结果不一，导致其作用仍存争议。本研究旨在探讨MDRT能否使OP MBC患者的全身治疗持续时间延长≥6个月。方法：本回顾性队列研究纳入了2017年12月至2023年3月期间因OP疾病接受MDRT的MBC患者。排除了接受脑部MDRT的患者。病历资料回顾截至2024年7月。主要终点是MDRT后继续接受相同全身治疗≥6个月的患者比例。结果：共纳入52例接受MDRT治疗的OP MBC患者，其中36例（69%）为HR+/HER2-疾病，10例（19%）为HER2+疾病，6例（12%）为三阴性乳腺癌（TNBC）。在47例有随访数据的患者中，28例（60%）在6个月时仍在接受原全身治疗，包括HR+/HER2-疾病患者的65%（22/34）、HER2+疾病患者的56%（5/9）和TNBC患者的25%（1/4）（p=0.30）。在MDRT后随访时间至少1年的38例患者中，47%（18/38）仍在接受相同的全身治疗。至下一次全身治疗的中位时间和中位无进展生存期（PFS）分别为6.9个月（95% CI，5.7–14.7）和6.2个月（95% CI，4.1–9.7）。结论：超过半数的OP MBC患者在MDRT后继续接受相同全身治疗至少6个月，这表明MDRT可能有助于延长特定患者的全身治疗持续时间。

原文链接：

Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer